Breu V - Search Results

1

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W, et al. Clozel M, et al. Among authors: breu v. J Pharmacol Exp Ther. 1994 Jul;270(1):228-35. J Pharmacol Exp Ther. 1994. PMID: 8035319

2

The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo.

Clozel M, Gray GA, Breu V, Löffler BM, Osterwalder R. Clozel M, et al. Among authors: breu v. Biochem Biophys Res Commun. 1992 Jul 31;186(2):867-73. doi: 10.1016/0006-291x(92)90826-7. Biochem Biophys Res Commun. 1992. PMID: 1323294

3

In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology.

Clozel M, Breu V, Gray GA, Löffler BM. Clozel M, et al. Among authors: breu v. J Cardiovasc Pharmacol. 1993;22 Suppl 8:S377-9. doi: 10.1097/00005344-199322008-00099. J Cardiovasc Pharmacol. 1993. PMID: 7509992

4

Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors.

Breu V, Hashido K, Broger C, Miyamoto C, Furuichi Y, Hayes A, Kalina B, Löffler BM, Ramuz H, Clozel M. Breu V, et al. Eur J Biochem. 1995 Jul 1;231(1):266-70. Eur J Biochem. 1995. PMID: 7628480 Free article.

Based on this model, 18 amino acids located at the inside of the receptor were mutated and analyzed for binding of the natural ligand endothelin-1 and bosentan, a recently described potent orally active endothelin antagonist [Clozel, M., Breu, V., Gray, G., Kalina, …

Based on this model, 18 amino acids located at the inside of the receptor were mutated and analyzed for binding of the natural ligand endoth …

5

Role of endothelin during reperfusion after ischemia in isolated perfused rat heart.

Dagassan PH, Breu V, Clozel M, Clozel JP. Dagassan PH, et al. Among authors: breu v. J Cardiovasc Pharmacol. 1994 Dec;24(6):867-74. doi: 10.1097/00005344-199424060-00003. J Cardiovasc Pharmacol. 1994. PMID: 7898067

6

Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma.

Löffler BM, Breu V, Clozel M. Löffler BM, et al. Among authors: breu v. FEBS Lett. 1993 Oct 25;333(1-2):108-10. doi: 10.1016/0014-5793(93)80384-7. FEBS Lett. 1993. PMID: 8224145 Free article.

7

In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors.

Breu V, Löffler BM, Clozel M. Breu V, et al. FEBS Lett. 1993 Nov 15;334(2):210-4. doi: 10.1016/0014-5793(93)81713-a. FEBS Lett. 1993. PMID: 8224248 Free article.

8

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist.

Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, Hirth G, Löffler BM, Müller M, Neidhart W, et al. Clozel M, et al. Among authors: breu v. Nature. 1993 Oct 21;365(6448):759-61. doi: 10.1038/365759a0. Nature. 1993. PMID: 8413655

9

Endothelin receptors that modulate contraction of the rat fundus.

Gray GA, Breu V, Clozel M. Gray GA, et al. Among authors: breu v. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S126-9. J Cardiovasc Pharmacol. 1995. PMID: 8587339

10

In vitro characterisation of Ro 46-8443, the first non-peptide antagonist selective for the endothelin ETB receptor.

Breu V, Clozel M, Burri K, Hirth G, Neidhart W, Ramuz H. Breu V, et al. FEBS Lett. 1996 Mar 25;383(1-2):37-41. doi: 10.1016/0014-5793(96)00213-x. FEBS Lett. 1996. PMID: 8612786 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters